GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SynCore Biotechnology Co Ltd (ROCO:4192) » Definitions » Change In Receivables

SynCore Biotechnology Co (ROCO:4192) Change In Receivables : NT$-0.20 Mil (TTM As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is SynCore Biotechnology Co Change In Receivables?

SynCore Biotechnology Co's change in receivables for the quarter that ended in Mar. 2024 was NT$0.67 Mil. It means SynCore Biotechnology Co's Accounts Receivable declined by NT$0.67 Mil from Dec. 2023 to Mar. 2024 .

SynCore Biotechnology Co's change in receivables for the fiscal year that ended in Dec. 2023 was NT$-0.79 Mil. It means SynCore Biotechnology Co's Accounts Receivable increased by NT$0.79 Mil from Dec. 2022 to Dec. 2023 .

SynCore Biotechnology Co's Accounts Receivable for the quarter that ended in Mar. 2024 was NT$1.99 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. SynCore Biotechnology Co's Days Sales Outstanding for the three months ended in Mar. 2024 was 41.48.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. SynCore Biotechnology Co's liquidation value for the three months ended in Mar. 2024 was NT$227.03 Mil.


SynCore Biotechnology Co Change In Receivables Historical Data

The historical data trend for SynCore Biotechnology Co's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SynCore Biotechnology Co Change In Receivables Chart

SynCore Biotechnology Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.23 0.10 -0.64 -0.11 -0.79

SynCore Biotechnology Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.08 0.03 -0.47 -0.42 0.67

SynCore Biotechnology Co Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-0.20 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SynCore Biotechnology Co  (ROCO:4192) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

SynCore Biotechnology Co's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=1.99/4.378*91
=41.48

2. In Ben Graham's calculation of liquidation value, SynCore Biotechnology Co's accounts receivable are only considered to be worth 75% of book value:

SynCore Biotechnology Co's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=248.415-26.898+0.75 * 1.99+0.5 * 8.047
=227.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SynCore Biotechnology Co Change In Receivables Related Terms

Thank you for viewing the detailed overview of SynCore Biotechnology Co's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


SynCore Biotechnology Co (ROCO:4192) Business Description

Traded in Other Exchanges
N/A
Address
No.84 Zhongshan Road, Zhongshan Village, Dongshan Township, Yilan, TWN, 269
SynCore Biotechnology Co Ltd is a biopharmaceutical company. Its pipeline products concentrate on the ophthalmology, oncology, and dermatology fields. The pipeline products of the company include SB01 and 02, SB03, SB04, and SB05. It is engaged in drug development and sale, food advisory, medicine inspection, biotechnology service and intellectual property. It operates in a single industry, the new drug development.

SynCore Biotechnology Co (ROCO:4192) Headlines

No Headlines